Safety of warfarin therapy in chronic hemodialysis patients: a prospective cohort study

Clinical and Experimental Nephrology

Volumn 20, Issue 5, 2016, Pages 787-794

  Hayashi, Matsuhiko ^a   Abe, Takayuki ^a   Iwai, Mieko ^a   Matsui, Ayumi ^a   Yoshida, Tadashi ^a   Sato, Yuji ^a   Kanno, Yoshihiko ^a,b   the Warfarin Study Group, ^c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c Tokyo Medical University ^*

Author keywords

Anticoagulation; Atrial fibrillation; Calciphylaxis; Cardiovascular disease; Hemodialysis

Indexed keywords

ANTITHROMBOCYTIC AGENT; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CALCINOSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG FATALITY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; ADVERSE EFFECTS; BLEEDING; CALCIPHYLAXIS; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; JAPAN; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PERIPHERAL ARTERIAL DISEASE; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTOR; STROKE; TIME FACTOR; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTICOAGULANTS; CALCIPHYLAXIS; CHI-SQUARE DISTRIBUTION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TOKYO; TREATMENT OUTCOME; WARFARIN;

EID: 84949511355     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-015-1205-0     Document Type: Article

References (22)

1. Foley RN1, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(Suppl 3):S112–S119.
2. Nakai S, Iseki K, Itami N, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2009). Ther Apher Dial. 2012;16:11–53.
3. Vázquez E1, Sánchez-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000;140:886–890.
4. Genovesi S1, Vincenti A, Rossi E, et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 2008;51:255–262.
5. Vazquez E, Sanchez-Perales C, Garcia-Garcia F, et al. Atrial fibrillation in incident dialysis patients. Kidney Int. 2009;76:324–30.
6. Wizemann V1, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098–1106.
7. Fujii H, Kim JI, Yoshiya K, et al. Clinical characteristics and cardiovascular outcomes of hemodialysis patients with atrial fibrillation: a prospective follow-up study. Am J Nephrol. 2011;34:126–34.
8. Winkelmayer WC, Patrick AR, Liu J, et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol. 2011;22:349–57.
9. Zimmerman D, Sood MM, Rigatto C, et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant. 2012;27:3816–22.
10. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–35.
11. Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med. 2011;365:1052–4.
12. You JJ1, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e531S–e575S.
13. Chan KE, Lazarus JM, Thadhani R, et al. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol. 2009;20:872–81.
14. Chan KE, Lazarus JM, Thadhani R, et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223–33.
15. Phelan PJ, O’Kelly P, Holian J, et al. Warfarin use in hemodialysis patients: what is the risk? Clin Nephrol. 2011;75:204–11.
16. Winkelmayer WC, Liu J, Setoguchi S, et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol. 2011;6:2662–8.
17. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196–203.
18. Genovesi S, Rossi E, Gallieni M, et al. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant. 2015;30:491–8.
19. Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27:1580–4.
20. JCS Joint Working Group. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). Circ J. 2014;78:1997–2021.
21. Knoll F, Sturm G, Lamina C, et al. Coumarins and survival in incident dialysis patients. Nephrol Dial Transplant. 2012;27:332–3.
22. Wakasugi M, Kazama JJ, Tokumoto A, et al. Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation: a prospective cohort study. Clin Exp Nephrol. 2014;18:662–9.